DOCKET NO.: CELG-0085

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#27

Re Application of:

Atul M. Mehta, Andrew L. Zeitlin,

Maghsound M. Dariani

Confirmation No.: 8327

Patent No.: 6,635,284 B2

Issued: October 21, 2003

Application No.: 09/038,470

Filing Date: March 11, 1998

For: Delivery Of Multiple Doses Of Medications

DATE OF DEPOSIT: February 16, 2005

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

TYPED NAME: Richard D. Watkins REGISTRATION NO.: 50,993

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

REQUEST FOR CERTIFICATE OF CORRECTION OF PATENT FOR PTO MISTAKE PURSUANT TO 37 CFR § 1.322(a)

It is respectfully requested that a Certificate of Correction be issued for the above-identified patent. In accordance with 37 CFR § 1.322(a), the patent has errors in it that occurred through the fault of the Patent and Trademark Office as clearly disclosed by the records and files of the office.

Enclosed herewith please find a completed Certificate of Correction form.

Since the errors are not due to applicants' mistake, no correction fee is due. Please charge any fees for copies and any additional fees to our Deposit Account No. 23-3050. This letter is enclosed in duplicate.

DOCKET NO.: CELG-0085

Date: February 16, 2005

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

PATENT

Richard D. Watkins Registration No. 50,993

© 2005 WW

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO :

6,635,284 B2

DATED

October 21, 2003

INVENTOR(S):

Atul M. Mehta, Andrew L. Zeitlin, Maghsound M. Dariani

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Coversheet, (73), delete "Celegene" and insert -- Celgene--

MAILING ADDRESS OF SENDER: Woodcock Washburn

PATENT NO. 6,635,284 B2

One Liberty Place, 46th Floor

No. of additional copies

Philadelphia, PA 19103



This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed inform to the USPTO. Time will vary depending on individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO :

6,635,284 B2

DATED

October 21, 2003

INVENTOR(S):

Atul M. Mehta, Andrew L. Zeitlin, Maghsound M. Dariani

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Jaroze Coversheet, (73), delete "Celegene" and insert -- Celgene-

MAILING ADDRESS OF SENDER: Woodcock Washburn

One Liberty Place, 46th Floor

Philadelphia, PA 19103

PATENT NO. 6,635,284 B2

No. of additional copies

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,635,284 B2 Page 1 of 1

DATED : October 21, 2003 INVENTOR(S) : Atul M. Mehta, Andrew L. Zeitlin and Maghsound M. Dariani

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page,

Item [73], Assignee, delete "Celegene" and insert -- Celgene --

Signed and Sealed this

Fifth Day of April, 2005

JON W. DUDAS Director of the United States Patent and Trademark Office





JWC/KUW

UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

JULY 24, 2004

PTAS

102651726A

WOODCOCK WASHBURN LLP JOHN W. CALDWELL, ESQ. ONE LIBERTY PLACE, 46TH FLOOR PHILADELPHIA, PA 19103-7301

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 01/20/2004

REEL/FRAME: 014885/0815

NUMBER OF PAGES: 4

BRIEF:

CROSS-REFERENCE OF ASSIGNMENT FILED IN UNITED STATES APPLICATION

NO. 09694217, RECORDED ON 1-18-01 AT REEL 011469 AND FRAME 0882.

ASSIGNOR:

MEHTA, ATUL M.

DOC DATE: 12/17/2003

ASSIGNEE:

CELGENE CORPORATION
7 POWDER HORN DRIVE
WARREN, NEW JERSEY 07059

SERIAL NUMBER: 09038470 PATENT NUMBER: 6635284

FILING DATE: 03/11/1998 ISSUE DATE: 10/21/2003

TITLE: DELIVERY OF MULTIPLE DOSES OF MEDICATIONS

014885/0815 PAGE 2

MAURICE CARTER, PARALEGAL ASSIGNMENT DIVISION OFFICE OF PUBLIC RECORDS

To The Honorable Commissioner of Patents and aginal documents or copy thereof. 1. Name of conveying party(ies): December 17, 2003 Atul M. Mehta Name: Celgene Corporation Date of Execution First Assignor Street Address: 7 Powder Horn Drive Date of Execution Second Assignor City: Warren State: New Jersey ZIP: 07059 Third Assignor Date of Execution Additional name(s) & address attached? \(\subseteq \text{YES} \subseteq \text{NO} \) 3. Nature of Conveyance (check only one): Fourth Assignor Date of Execution ☐ New Assignment Merger License Agreement Security Agreement Fifth Assignor Date of Execution Change of Name Other: Cross-reference of Assignment filed in United States Sixth Assignor Date of Execution Application No. 09/694,217, recorded on 1/18/01 at Reel No. 011469 and Frame No. 0882. Additional name(s) of conveying party(ies) attached? YES NO 4. Identification of Application number(s), patent number(s) OR date of execution of application to which assignment refers: Application Nos.: Patent Nos.: Date application was signed by the first named executing inventor 6,635,284 (Fill-in this date only if assignment is filed together with a new application) 5. Name and address of party to whom correspondence concerning documents should be mailed: 6. Total number of applications and patents involved: 1 Name: John W. Caldwell, Esq. 7. Total fee (37 CFR 3.41): \$40.00 WOODCOCK WASHBURN LLP ⊠ Enclosed One Liberty Place - 46th Floor Authorized to be charged to Deposit Account Number Philadelphia, Pennsylvania 19103-7301 215-568-3100 8. Please charge any deficiency or credit any overpayment to 011/21/2004 DBYRNE 00000004 6635284 Deposit Account Number 23-3050 01 FC:8021 40.00 OP DO NOT USE THIS SPACE 9. Statement and signature. To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. Janet T. Griffin Name of Person Signing Total number of pages including cover sheet, assignment document and additional pages attached thereto: 4 Mail documents to be recorded with required cover sheet information to: Mail Stop Assignment Recordation Services Commissioner for Patents

P.O. Box 1450 Alexandria, VA 22313-1450



ASSIGNMENT

This Assignment is effective as of the date of the last signature of the Parties, and is from Atul M. Mehta, Ph.D., a citizen of the United States residing at 76 Walsh Drive, Mahwah, NJ 07430-2565 ("Mehta"), to Celgene Corporation, a Delaware corporation, and having a place of business at 7 Powder Horn Drive, Warren, New Jersey 07059 ("Celgene").

RECITALS:

- A. Pursuant to a Research & Development Agreement dated May 2, 1996 between Elite Laboratories, Inc. ("Elite") and Celgene ("R&D Agreement"), Elite developed a controlled release dosage formulation of methylphenidate having a release profile specified by Celgene, and Celgene filed United States Patent Application No. 09/038,470 on March 11, 1998 entitled Delivery of Multiple Doses of Medications, also identified as Woodcock Docket No. CELG-0085 (a divisional application of 08/892,190), based on such development in the names of Mehta and his collaborators at Celgene which has issued as U.S. Patent No. 6,635,284 on October 21, 2003 (the "Patent").
- B. The R&D Agreement, a letter agreement between Elite and Celgene dated May 6, 1997 ("First Letter Agreement"), and a further letter agreement between Elite and Celgene dated November 11, 1998 ("Second Letter Agreement") obligate Mehta to assign his rights in the Patent to Celgene and obligate Celgene to grant back to Elite an exclusive license under the Patent outside the field of methylphenidate drugs.
- C. Mehta, accordingly, wishes to assign his rights in the Patent, and Celgene wishes to receive this assignment.

NOW, THEREFORE, the parties covenant and agree as follows:

- (1) Mehta hereby sells, assigns, transfers and sets over to Celgene his entire right, title and interest in and to the Patent, and all reissues, re-examinations, and extensions thereof,
- the same to be held and enjoyed by Celgene, its successors, assigns, nominees or legal representatives, to the full end of the term for which the Patent, and *any* reissue or reexamination thereof, has been granted, or may be extended, as fully and entirely as the same would have been held by Mehta had this assignment, sale and transfer not been made.
- (2) Mehta represents that he has the full right to convey his entire interest herein assigned, and that he has not executed and will not execute any agreement in conflict herewith. Mehta agrees that he will execute such additional papers provided by Celgene as may be reasonably necessary or desirable to confirm or perfect this Assignment, if any, and he further agrees to communicate to Celgene or its nominee all pertinent facts relating to the invention of the Patent and to give such testimony regarding the invention as may be reasonably necessary in legal proceedings concerning the patent, provided that Celgene shall pay to Mehta his expenses and his consulting fee (\$400.00/hr) for his time spent in doing so.

Joint Inventors/Contributors

- (3) Celgene acknowledges that commencing prior to entering into the R&D Agreement with Celgene, Elite has applied its technology to develop controlled release dosage formulations of drugs other than methylphenidate and that nothing in this Assignment derogates from Elite's right to continue doing so. Celgene agrees that it shall not use the technology disclosed to it in confidence by Elite in the course of Elite's performance under the R&D Agreement in connection with any drug other than methylphenidate, and Celgene acknowledges that the R&D Agreement, the First Letter Agreement and the Second Letter Agreement remain in full force and effect.
- (4) This Assignment shall be binding upon the successors and assigns of Mehta and Celgene, and shall inure to the benefit of the successors and assigns of Mehta and Celgene.

IN WITNESS WHEREOF, the Parties have executed this document as follows:

12-17-03 Date	Atul M. Mehta, Ph.D.	(L.S.)
<u>Hec. 19, 2ω)</u> Date	Sol 3. Barer President - Celgene Corporation	(L.S.)

STATE OF New Jersey: ss COUNTY OF Bergen: ss

On this 17th day of December, year of 2003, before me personally came the above named Atul M. Mehta, Ph.D. to me personally known and known to me to be the same individual who executed the foregoing assignment, and who acknowledged to me that execution of the same was of that person's own free will for the use and purposes therein set forth.

Notary Public

. . . .

STATE OF New Jersey:

SS

DOCKET NO.: CELG-0085

3

PATENT Joint Inventors/Contributors

COUNTY OF Somerset:

On this 19¹⁶ day of Decamber, year of 2003, before me personally came the above named Sol J. Barer to me personally known and known to me to be the same individual who executed the foregoing assignment, and who acknowledged to me that execution of the same was of that person's own free will for the use and purposes therein set forth.

Notary Public

JUDITH MARY PITHA NOTARY PUBLIC OF NEW JERGEY

MY COMMISSION EXPIRES AUG. 28, 2005